15.33MMarket Cap-5899P/E (TTM)
2.750High2.650Low1.96KVolume2.700Open2.770Pre Close5.29KTurnover0.04%Turnover RatioLossP/E (Static)5.70MShares5.96052wk High1.30P/B12.68MFloat Cap1.48152wk Low--Dividend TTM4.71MShs Float28.990Historical High--Div YieldTTM3.61%Amplitude1.390Historical Low2.699Avg Price1Lot Size
Immuron Stock Forum
Immuron Limited (NASDAQ: IMRN), an Australian biopharmaceutical company, has recently announced positive results that support the progress of its flagship product, Travelan®, into Phase 3 Clinical Trials in the United States. This significant development could potentially have far-reaching impacts on the global pharmaceutical landscape. $Immuron (IMRN.US)$